SCHEMBL7469718

SCHEMBL7469718

Cn1cc(CCC=O)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KCNH2 Q12809 2/20 0.36
PDE10A Q9Y233 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRA5 P31644 1/20 0.35
PDE8B O95263 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.34
HTT P42858 1/20 0.34
SCN2A Q99250 1/20 0.34
CECR2 Q9BXF3 1/20 0.34
BAZ2B Q9UIF8 1/20 0.34
BAZ2A Q9UIF9 1/20 0.34
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509000 0.82
SCHEMBL6133076 0.80 PDE10A (0.41) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL16831418 0.78 GAA (0.39) ALDH1A1GAAKMT2AKCNH2TP53
SCHEMBL16708779 0.76 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL8342570 0.75
SCHEMBL16802678 0.75 TLR7 (0.35) L3MBTL1
SCHEMBL7941493 0.74 PDE8B (0.38) ALDH1A1SMN1; SMN2GAAMEN1KMT2A
SCHEMBL23678033 0.74
SCHEMBL18444926 0.74
SCHEMBL1751510 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102216299-B 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors MERCK PATENT GMBH 2015-02-11 CN claimed
CN-119698412-A 5-HT2A receptor agonist, and preparation method and application thereof 上海翊石医药科技有限公司 2025-03-25 CN disclosed
WO-2025021120-A1 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2025-01-30 WO disclosed
US-20240150349-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2024-05-09 US disclosed
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 EP disclosed
EP-3681885-B1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS INC (US) 2024-02-28 EP disclosed
CN-117069720-A 5-HT 2A Receptor agonist, preparation method and application thereof 上海翊石医药科技有限公司 2023-11-17 CN disclosed
US-20230365542-A1 Selective Agonists of 5-HT2A Receptor and Methods of Use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-16 US disclosed
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors FORMA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20230265080-A1 MODULATORS OF ALPHA-1 ANTITRYPSIN VERTEX PHARMA (US) 2023-08-24 US disclosed
EP-3681885-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS Forma Therapeutics, Inc. (US) 2020-07-22 EP disclosed
US-20200216445-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. 2020-07-09 US disclosed
WO-2020081257-A1 MODULATORS OF ALPHA-1 ANTITRYPSIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2020-04-23 WO disclosed
WO-2019055877-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-03-21 WO disclosed
WO-2019055877-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-03-21 WO disclosed
WO-2018219478-A1 HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS ORYZON GENOMICS, S.A. (ES) 2018-12-06 WO disclosed
WO-2016180247-A1 BICYCLIC COMPOUND USED AS AN LP-PLA2 INHIBITOR, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF 中国科学院上海药物研究所 2016-11-17 WO disclosed
EP-0873320-B1 PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO (JP) 2002-06-12 EP disclosed
US-20020010182-A1 Piperazine derivatives as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-24 US disclosed
US-6087357-A Piperazine derivatives as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365542-A1 Selective Agonists of 5-HT2A Receptor and Methods of Use HTR2A, HTR2C, HTR2B ALDH1A1 857/4885SMN1; SMN2 488/4885GAA 2938/4885
US-20200216445-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 ALDH1A1 3405/4885SMN1; SMN2 2738/4885GAA 2385/4885
US-20020010182-A1 Piperazine derivatives as tachykinin antagonists PKD2, SSTR5, TAC3 ALDH1A1 2739/4885SMN1; SMN2 3031/4885GAA 3245/4885
US-20240150349-A1 TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS EP300, CREBBP, BRD3 ALDH1A1 3405/4885SMN1; SMN2 2738/4885GAA 2385/4885
US-20230265080-A1 MODULATORS OF ALPHA-1 ANTITRYPSIN SERPINA2, SERPINA3, SERPINB1 ALDH1A1 664/4885SMN1; SMN2 2183/4885GAA 142/4885
US-11787803-B2 Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors EP300, CREBBP, BRD3 ALDH1A1 3405/4885SMN1; SMN2 2738/4885GAA 2385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.